Being prescribed semaglutide, the active ingredient in Ozempic and Wegovy, increases a person’s chance of developing a sight-threatening condition, a Harvard study published on Wednesday found.
The JAMA Network Open study found that diabetic patients prescribed semaglutide had more than four times the chance of developing non-arteritic anterior ischemic optic neuropathy when compared to other diabetic patients.
Non-arteritic anterior ischemic optic neuropathy (NAION) occurs when the optic nerves in the eyes are damaged due to insufficient blood flow, causing vision loss.
NAION is the second most common optic neuropathy condition with the first being glaucoma. […]
– Read More: www.theepochtimes.com
